A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
Trial details
- Registry ID
- NCT07200908
- Drugs studied
- Brelovitug 300 mg, Bulevirtide 2 mg and Brelovitug - 300 mg
TrialRedline tracks 19 clinical trials sponsored by Mirum Pharmaceuticals, Inc.: 9 Phase 3, 2 Phase 2 / 3, 8 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving BulevirtideNCT07454837 | Brelovitug (BJT-778), Bulevirtide | Recruiting | 2027-08-31Estimated |
| A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta InfectionNCT06907290 | Brelovitug 300 mg, Brelovitug 900 mg, Delayed Treatment with Brelovitug 300mg | Active not recruiting | 2029-05Estimated |
Names as written in the registry records.
NCT06553768 · Mirum Pharmaceuticals, Inc.
Before: Estimated. After: Actual.
Before: Oct 2026. After: 29 Jul 2026.
NCT04663308 · Mirum Pharmaceuticals, Inc.
Before: Estimated. After: Actual.
Before: Jun 2026. After: 20 Feb 2026.
NCT05050136 · Mirum Pharmaceuticals, Inc.
Before: Estimated. After: Actual.
Before: 260 participants (planned). After: 333 participants (actual).
Before: Apr 2027. After: Jan 2027.
Before: Recruiting. After: Active not recruiting.
NCT07298330 · Mirum Pharmaceuticals, Inc.
Before: Recruiting. After: Active not recruiting.
NCT04185363 · Mirum Pharmaceuticals, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Incidence of Treatment Emergent Adverse Events (TEAEs) during the study. After: Measure: Mean Change From Baseline Over Time in the Average Morning ItchRO(Obs) Severity Score.
Before: 90 participants (actual). After: 84 participants (actual).
NCT06553768 · Mirum Pharmaceuticals, Inc.
Before: Recruiting. After: Active not recruiting.
NCT06907290 · Mirum Pharmaceuticals, Inc.
Before: Jun 2027. After: May 2029.
Before: Recruiting. After: Active not recruiting.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Frequency of treatment-emergent adverse events [TEAEs]. After: Measure: Frequency of Treatment-emergent Adverse Events [TEAEs].